Dr. Chen is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Elm And Carlton St
Buffalo, NY 14263Phone+1 716-845-2300Fax+1 716-845-1110
Education & Training
Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2006 - 2009
University at BuffaloResidency, Internal Medicine, 2003 - 2006
Shanghai Medical UniversityClass of 1992
Certifications & Licensure
NY State Medical License 2009 - 2025
MD State Medical License 2006 - 2010- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC) Start of enrollment: 2015 Jun 26
- Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
- Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
- Join now to see all
Publications & Presentations
PubMed
- Patients' Preferences for Adjuvant Osimertinib in Non-Small-Cell Lung Cancer After Complete Surgical Resection: What Makes It Worth It to Patients?Muhammad Awidi, Angel Mier-Hicks, Stuthi Perimbeti, Kristopher Attwood, Hongbin Chen
Clinical Lung Cancer. 2024-09-01 - 1 citationsFluctuations in Gut Microbiome Composition During Immune Checkpoint Inhibitor Therapy.Joy Sarkar, Eduardo Cortes Gomez, Takaaki Oba, Hongbin Chen, Grace K Dy
World Journal of Oncology. 2023-06-01 - 4 citationsPredictive and Prognostic Implications of Circulating CX3CR1CD8T Cells in Non-Small Cell Lung Cancer Patients Treated with Chemo-Immunotherapy.Eihab Abdelfatah, Mark D Long, Ryutaro Kajihara, Takaaki Oba, Takayoshi Yamauchi
Cancer Research Communications. 2023-03-01
Press Mentions
- Roswell Park Researchers Identify New Biomarker of Response to Checkpoint InhibitorsMarch 3rd, 2021
- Predisposing Factors and Radiological Features in Patients with Internal Carotid Artery Dissection or Vertebral Artery DissectionDecember 10th, 2020
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
